0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Chronic Spontaneous Urticaria Market Research Report 2025
Published Date: April 2025
|
Report Code: QYRE-Auto-34D13219
Home | Market Reports | Health| Health Conditions| Skin Conditions
Global Chronic Spontaneous Urticaria Market Research Report 2023
BUY CHAPTERS

Global Chronic Spontaneous Urticaria Market Research Report 2025

Code: QYRE-Auto-34D13219
Report
April 2025
Pages:91
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Chronic Spontaneous Urticaria Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Chronic Spontaneous Urticaria Market

Chronic Spontaneous Urticaria Market

The global market for Chronic Spontaneous Urticaria was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Chronic Spontaneous Urticaria, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Spontaneous Urticaria.
The Chronic Spontaneous Urticaria market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chronic Spontaneous Urticaria market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Spontaneous Urticaria companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Chronic Spontaneous Urticaria Market Report

Report Metric Details
Report Name Chronic Spontaneous Urticaria Market
CAGR 5%
Segment by Type
Segment by Application
  • Children
  • Adult
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Mylan N. V., Sanofi, GlaxoSmithKline, Bayer, Merck, Aurobindo Pharma, Hikma Pharmaceuticals, WOCKHARDT, AbbVie, Inc., Cipla Inc., F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries, Ltd., Pfizer, Inc., Novartis AG, Eli Lilly and Company, Allergan, Lupin
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Chronic Spontaneous Urticaria company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Chronic Spontaneous Urticaria Market report?

Ans: The main players in the Chronic Spontaneous Urticaria Market are Mylan N. V., Sanofi, GlaxoSmithKline, Bayer, Merck, Aurobindo Pharma, Hikma Pharmaceuticals, WOCKHARDT, AbbVie, Inc., Cipla Inc., F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries, Ltd., Pfizer, Inc., Novartis AG, Eli Lilly and Company, Allergan, Lupin

What are the Application segmentation covered in the Chronic Spontaneous Urticaria Market report?

Ans: The Applications covered in the Chronic Spontaneous Urticaria Market report are Children, Adult

What are the Type segmentation covered in the Chronic Spontaneous Urticaria Market report?

Ans: The Types covered in the Chronic Spontaneous Urticaria Market report are Antihistamine, Monoclonal Antibody, Other

Recommended Reports

Allergy Treatment Drugs

Urticaria & Related

Autoimmune & Skin

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Chronic Spontaneous Urticaria Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antihistamine
1.2.3 Monoclonal Antibody
1.2.4 Other
1.3 Market by Application
1.3.1 Global Chronic Spontaneous Urticaria Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Children
1.3.3 Adult
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Chronic Spontaneous Urticaria Market Perspective (2020-2031)
2.2 Global Chronic Spontaneous Urticaria Growth Trends by Region
2.2.1 Global Chronic Spontaneous Urticaria Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Chronic Spontaneous Urticaria Historic Market Size by Region (2020-2025)
2.2.3 Chronic Spontaneous Urticaria Forecasted Market Size by Region (2026-2031)
2.3 Chronic Spontaneous Urticaria Market Dynamics
2.3.1 Chronic Spontaneous Urticaria Industry Trends
2.3.2 Chronic Spontaneous Urticaria Market Drivers
2.3.3 Chronic Spontaneous Urticaria Market Challenges
2.3.4 Chronic Spontaneous Urticaria Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Chronic Spontaneous Urticaria Players by Revenue
3.1.1 Global Top Chronic Spontaneous Urticaria Players by Revenue (2020-2025)
3.1.2 Global Chronic Spontaneous Urticaria Revenue Market Share by Players (2020-2025)
3.2 Global Chronic Spontaneous Urticaria Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Chronic Spontaneous Urticaria Revenue
3.4 Global Chronic Spontaneous Urticaria Market Concentration Ratio
3.4.1 Global Chronic Spontaneous Urticaria Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Chronic Spontaneous Urticaria Revenue in 2024
3.5 Global Key Players of Chronic Spontaneous Urticaria Head office and Area Served
3.6 Global Key Players of Chronic Spontaneous Urticaria, Product and Application
3.7 Global Key Players of Chronic Spontaneous Urticaria, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Chronic Spontaneous Urticaria Breakdown Data by Type
4.1 Global Chronic Spontaneous Urticaria Historic Market Size by Type (2020-2025)
4.2 Global Chronic Spontaneous Urticaria Forecasted Market Size by Type (2026-2031)
5 Chronic Spontaneous Urticaria Breakdown Data by Application
5.1 Global Chronic Spontaneous Urticaria Historic Market Size by Application (2020-2025)
5.2 Global Chronic Spontaneous Urticaria Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Chronic Spontaneous Urticaria Market Size (2020-2031)
6.2 North America Chronic Spontaneous Urticaria Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Chronic Spontaneous Urticaria Market Size by Country (2020-2025)
6.4 North America Chronic Spontaneous Urticaria Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Chronic Spontaneous Urticaria Market Size (2020-2031)
7.2 Europe Chronic Spontaneous Urticaria Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Chronic Spontaneous Urticaria Market Size by Country (2020-2025)
7.4 Europe Chronic Spontaneous Urticaria Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Chronic Spontaneous Urticaria Market Size (2020-2031)
8.2 Asia-Pacific Chronic Spontaneous Urticaria Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Chronic Spontaneous Urticaria Market Size by Region (2020-2025)
8.4 Asia-Pacific Chronic Spontaneous Urticaria Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Chronic Spontaneous Urticaria Market Size (2020-2031)
9.2 Latin America Chronic Spontaneous Urticaria Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Chronic Spontaneous Urticaria Market Size by Country (2020-2025)
9.4 Latin America Chronic Spontaneous Urticaria Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Chronic Spontaneous Urticaria Market Size (2020-2031)
10.2 Middle East & Africa Chronic Spontaneous Urticaria Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Chronic Spontaneous Urticaria Market Size by Country (2020-2025)
10.4 Middle East & Africa Chronic Spontaneous Urticaria Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Mylan N. V.
11.1.1 Mylan N. V. Company Details
11.1.2 Mylan N. V. Business Overview
11.1.3 Mylan N. V. Chronic Spontaneous Urticaria Introduction
11.1.4 Mylan N. V. Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.1.5 Mylan N. V. Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Details
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Chronic Spontaneous Urticaria Introduction
11.2.4 Sanofi Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.2.5 Sanofi Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Details
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Chronic Spontaneous Urticaria Introduction
11.3.4 GlaxoSmithKline Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.3.5 GlaxoSmithKline Recent Development
11.4 Bayer
11.4.1 Bayer Company Details
11.4.2 Bayer Business Overview
11.4.3 Bayer Chronic Spontaneous Urticaria Introduction
11.4.4 Bayer Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.4.5 Bayer Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Chronic Spontaneous Urticaria Introduction
11.5.4 Merck Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.5.5 Merck Recent Development
11.6 Aurobindo Pharma
11.6.1 Aurobindo Pharma Company Details
11.6.2 Aurobindo Pharma Business Overview
11.6.3 Aurobindo Pharma Chronic Spontaneous Urticaria Introduction
11.6.4 Aurobindo Pharma Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.6.5 Aurobindo Pharma Recent Development
11.7 Hikma Pharmaceuticals
11.7.1 Hikma Pharmaceuticals Company Details
11.7.2 Hikma Pharmaceuticals Business Overview
11.7.3 Hikma Pharmaceuticals Chronic Spontaneous Urticaria Introduction
11.7.4 Hikma Pharmaceuticals Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.7.5 Hikma Pharmaceuticals Recent Development
11.8 WOCKHARDT
11.8.1 WOCKHARDT Company Details
11.8.2 WOCKHARDT Business Overview
11.8.3 WOCKHARDT Chronic Spontaneous Urticaria Introduction
11.8.4 WOCKHARDT Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.8.5 WOCKHARDT Recent Development
11.9 AbbVie, Inc.
11.9.1 AbbVie, Inc. Company Details
11.9.2 AbbVie, Inc. Business Overview
11.9.3 AbbVie, Inc. Chronic Spontaneous Urticaria Introduction
11.9.4 AbbVie, Inc. Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.9.5 AbbVie, Inc. Recent Development
11.10 Cipla Inc.
11.10.1 Cipla Inc. Company Details
11.10.2 Cipla Inc. Business Overview
11.10.3 Cipla Inc. Chronic Spontaneous Urticaria Introduction
11.10.4 Cipla Inc. Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.10.5 Cipla Inc. Recent Development
11.11 F. Hoffmann La Roche Ltd.
11.11.1 F. Hoffmann La Roche Ltd. Company Details
11.11.2 F. Hoffmann La Roche Ltd. Business Overview
11.11.3 F. Hoffmann La Roche Ltd. Chronic Spontaneous Urticaria Introduction
11.11.4 F. Hoffmann La Roche Ltd. Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.11.5 F. Hoffmann La Roche Ltd. Recent Development
11.12 Teva Pharmaceutical Industries, Ltd.
11.12.1 Teva Pharmaceutical Industries, Ltd. Company Details
11.12.2 Teva Pharmaceutical Industries, Ltd. Business Overview
11.12.3 Teva Pharmaceutical Industries, Ltd. Chronic Spontaneous Urticaria Introduction
11.12.4 Teva Pharmaceutical Industries, Ltd. Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.12.5 Teva Pharmaceutical Industries, Ltd. Recent Development
11.13 Pfizer, Inc.
11.13.1 Pfizer, Inc. Company Details
11.13.2 Pfizer, Inc. Business Overview
11.13.3 Pfizer, Inc. Chronic Spontaneous Urticaria Introduction
11.13.4 Pfizer, Inc. Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.13.5 Pfizer, Inc. Recent Development
11.14 Novartis AG
11.14.1 Novartis AG Company Details
11.14.2 Novartis AG Business Overview
11.14.3 Novartis AG Chronic Spontaneous Urticaria Introduction
11.14.4 Novartis AG Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.14.5 Novartis AG Recent Development
11.15 Eli Lilly and Company
11.15.1 Eli Lilly and Company Company Details
11.15.2 Eli Lilly and Company Business Overview
11.15.3 Eli Lilly and Company Chronic Spontaneous Urticaria Introduction
11.15.4 Eli Lilly and Company Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.15.5 Eli Lilly and Company Recent Development
11.16 Allergan
11.16.1 Allergan Company Details
11.16.2 Allergan Business Overview
11.16.3 Allergan Chronic Spontaneous Urticaria Introduction
11.16.4 Allergan Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.16.5 Allergan Recent Development
11.17 Lupin
11.17.1 Lupin Company Details
11.17.2 Lupin Business Overview
11.17.3 Lupin Chronic Spontaneous Urticaria Introduction
11.17.4 Lupin Revenue in Chronic Spontaneous Urticaria Business (2020-2025)
11.17.5 Lupin Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
 Table 1. Global Chronic Spontaneous Urticaria Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Antihistamine
 Table 3. Key Players of Monoclonal Antibody
 Table 4. Key Players of Other
 Table 5. Global Chronic Spontaneous Urticaria Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Chronic Spontaneous Urticaria Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Chronic Spontaneous Urticaria Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Chronic Spontaneous Urticaria Market Share by Region (2020-2025)
 Table 9. Global Chronic Spontaneous Urticaria Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Chronic Spontaneous Urticaria Market Share by Region (2026-2031)
 Table 11. Chronic Spontaneous Urticaria Market Trends
 Table 12. Chronic Spontaneous Urticaria Market Drivers
 Table 13. Chronic Spontaneous Urticaria Market Challenges
 Table 14. Chronic Spontaneous Urticaria Market Restraints
 Table 15. Global Chronic Spontaneous Urticaria Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Chronic Spontaneous Urticaria Market Share by Players (2020-2025)
 Table 17. Global Top Chronic Spontaneous Urticaria Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Spontaneous Urticaria as of 2024)
 Table 18. Ranking of Global Top Chronic Spontaneous Urticaria Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Chronic Spontaneous Urticaria Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Chronic Spontaneous Urticaria, Headquarters and Area Served
 Table 21. Global Key Players of Chronic Spontaneous Urticaria, Product and Application
 Table 22. Global Key Players of Chronic Spontaneous Urticaria, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Chronic Spontaneous Urticaria Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Chronic Spontaneous Urticaria Revenue Market Share by Type (2020-2025)
 Table 26. Global Chronic Spontaneous Urticaria Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Chronic Spontaneous Urticaria Revenue Market Share by Type (2026-2031)
 Table 28. Global Chronic Spontaneous Urticaria Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Chronic Spontaneous Urticaria Revenue Market Share by Application (2020-2025)
 Table 30. Global Chronic Spontaneous Urticaria Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Chronic Spontaneous Urticaria Revenue Market Share by Application (2026-2031)
 Table 32. North America Chronic Spontaneous Urticaria Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Chronic Spontaneous Urticaria Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Chronic Spontaneous Urticaria Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Chronic Spontaneous Urticaria Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Chronic Spontaneous Urticaria Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Chronic Spontaneous Urticaria Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Chronic Spontaneous Urticaria Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Chronic Spontaneous Urticaria Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Chronic Spontaneous Urticaria Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Chronic Spontaneous Urticaria Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Chronic Spontaneous Urticaria Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Chronic Spontaneous Urticaria Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Chronic Spontaneous Urticaria Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Chronic Spontaneous Urticaria Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Chronic Spontaneous Urticaria Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Mylan N. V. Company Details
 Table 48. Mylan N. V. Business Overview
 Table 49. Mylan N. V. Chronic Spontaneous Urticaria Product
 Table 50. Mylan N. V. Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 51. Mylan N. V. Recent Development
 Table 52. Sanofi Company Details
 Table 53. Sanofi Business Overview
 Table 54. Sanofi Chronic Spontaneous Urticaria Product
 Table 55. Sanofi Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 56. Sanofi Recent Development
 Table 57. GlaxoSmithKline Company Details
 Table 58. GlaxoSmithKline Business Overview
 Table 59. GlaxoSmithKline Chronic Spontaneous Urticaria Product
 Table 60. GlaxoSmithKline Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 61. GlaxoSmithKline Recent Development
 Table 62. Bayer Company Details
 Table 63. Bayer Business Overview
 Table 64. Bayer Chronic Spontaneous Urticaria Product
 Table 65. Bayer Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 66. Bayer Recent Development
 Table 67. Merck Company Details
 Table 68. Merck Business Overview
 Table 69. Merck Chronic Spontaneous Urticaria Product
 Table 70. Merck Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 71. Merck Recent Development
 Table 72. Aurobindo Pharma Company Details
 Table 73. Aurobindo Pharma Business Overview
 Table 74. Aurobindo Pharma Chronic Spontaneous Urticaria Product
 Table 75. Aurobindo Pharma Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 76. Aurobindo Pharma Recent Development
 Table 77. Hikma Pharmaceuticals Company Details
 Table 78. Hikma Pharmaceuticals Business Overview
 Table 79. Hikma Pharmaceuticals Chronic Spontaneous Urticaria Product
 Table 80. Hikma Pharmaceuticals Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 81. Hikma Pharmaceuticals Recent Development
 Table 82. WOCKHARDT Company Details
 Table 83. WOCKHARDT Business Overview
 Table 84. WOCKHARDT Chronic Spontaneous Urticaria Product
 Table 85. WOCKHARDT Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 86. WOCKHARDT Recent Development
 Table 87. AbbVie, Inc. Company Details
 Table 88. AbbVie, Inc. Business Overview
 Table 89. AbbVie, Inc. Chronic Spontaneous Urticaria Product
 Table 90. AbbVie, Inc. Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 91. AbbVie, Inc. Recent Development
 Table 92. Cipla Inc. Company Details
 Table 93. Cipla Inc. Business Overview
 Table 94. Cipla Inc. Chronic Spontaneous Urticaria Product
 Table 95. Cipla Inc. Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 96. Cipla Inc. Recent Development
 Table 97. F. Hoffmann La Roche Ltd. Company Details
 Table 98. F. Hoffmann La Roche Ltd. Business Overview
 Table 99. F. Hoffmann La Roche Ltd. Chronic Spontaneous Urticaria Product
 Table 100. F. Hoffmann La Roche Ltd. Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 101. F. Hoffmann La Roche Ltd. Recent Development
 Table 102. Teva Pharmaceutical Industries, Ltd. Company Details
 Table 103. Teva Pharmaceutical Industries, Ltd. Business Overview
 Table 104. Teva Pharmaceutical Industries, Ltd. Chronic Spontaneous Urticaria Product
 Table 105. Teva Pharmaceutical Industries, Ltd. Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 106. Teva Pharmaceutical Industries, Ltd. Recent Development
 Table 107. Pfizer, Inc. Company Details
 Table 108. Pfizer, Inc. Business Overview
 Table 109. Pfizer, Inc. Chronic Spontaneous Urticaria Product
 Table 110. Pfizer, Inc. Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 111. Pfizer, Inc. Recent Development
 Table 112. Novartis AG Company Details
 Table 113. Novartis AG Business Overview
 Table 114. Novartis AG Chronic Spontaneous Urticaria Product
 Table 115. Novartis AG Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 116. Novartis AG Recent Development
 Table 117. Eli Lilly and Company Company Details
 Table 118. Eli Lilly and Company Business Overview
 Table 119. Eli Lilly and Company Chronic Spontaneous Urticaria Product
 Table 120. Eli Lilly and Company Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 121. Eli Lilly and Company Recent Development
 Table 122. Allergan Company Details
 Table 123. Allergan Business Overview
 Table 124. Allergan Chronic Spontaneous Urticaria Product
 Table 125. Allergan Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 126. Allergan Recent Development
 Table 127. Lupin Company Details
 Table 128. Lupin Business Overview
 Table 129. Lupin Chronic Spontaneous Urticaria Product
 Table 130. Lupin Revenue in Chronic Spontaneous Urticaria Business (2020-2025) & (US$ Million)
 Table 131. Lupin Recent Development
 Table 132. Research Programs/Design for This Report
 Table 133. Key Data Information from Secondary Sources
 Table 134. Key Data Information from Primary Sources
 Table 135. Authors List of This Report


List of Figures
 Figure 1. Chronic Spontaneous Urticaria Picture
 Figure 2. Global Chronic Spontaneous Urticaria Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Chronic Spontaneous Urticaria Market Share by Type: 2024 VS 2031
 Figure 4. Antihistamine Features
 Figure 5. Monoclonal Antibody Features
 Figure 6. Other Features
 Figure 7. Global Chronic Spontaneous Urticaria Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Chronic Spontaneous Urticaria Market Share by Application: 2024 VS 2031
 Figure 9. Children Case Studies
 Figure 10. Adult Case Studies
 Figure 11. Chronic Spontaneous Urticaria Report Years Considered
 Figure 12. Global Chronic Spontaneous Urticaria Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 13. Global Chronic Spontaneous Urticaria Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Chronic Spontaneous Urticaria Market Share by Region: 2024 VS 2031
 Figure 15. Global Chronic Spontaneous Urticaria Market Share by Players in 2024
 Figure 16. Global Top Chronic Spontaneous Urticaria Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chronic Spontaneous Urticaria as of 2024)
 Figure 17. The Top 10 and 5 Players Market Share by Chronic Spontaneous Urticaria Revenue in 2024
 Figure 18. North America Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 19. North America Chronic Spontaneous Urticaria Market Share by Country (2020-2031)
 Figure 20. United States Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Canada Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Chronic Spontaneous Urticaria Market Share by Country (2020-2031)
 Figure 24. Germany Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. France Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. U.K. Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Italy Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Russia Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Nordic Countries Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Chronic Spontaneous Urticaria Market Share by Region (2020-2031)
 Figure 32. China Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Japan Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. South Korea Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Southeast Asia Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. India Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Australia Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Chronic Spontaneous Urticaria Market Share by Country (2020-2031)
 Figure 40. Mexico Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Brazil Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Chronic Spontaneous Urticaria Market Share by Country (2020-2031)
 Figure 44. Turkey Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Saudi Arabia Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. UAE Chronic Spontaneous Urticaria Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Mylan N. V. Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 48. Sanofi Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 49. GlaxoSmithKline Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 50. Bayer Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 51. Merck Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 52. Aurobindo Pharma Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 53. Hikma Pharmaceuticals Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 54. WOCKHARDT Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 55. AbbVie, Inc. Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 56. Cipla Inc. Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 57. F. Hoffmann La Roche Ltd. Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 58. Teva Pharmaceutical Industries, Ltd. Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 59. Pfizer, Inc. Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 60. Novartis AG Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 61. Eli Lilly and Company Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 62. Allergan Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 63. Lupin Revenue Growth Rate in Chronic Spontaneous Urticaria Business (2020-2025)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

RELATED REPORTS

Global Chronic Idiopathic Urticaria Treatment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-38H16391
Tue Sep 23 00:00:00 UTC 2025

Add to Cart

Global Fungal Skin Disease Diagnostic Equipment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-17T16810
Mon Sep 22 00:00:00 UTC 2025

Add to Cart

Global UVB Vitiligo Phototherapy Device Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-24Z16496
Mon Sep 22 00:00:00 UTC 2025

Add to Cart

Global Vitiligo Phototherapy Device Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-15I16746
Mon Sep 22 00:00:00 UTC 2025

Add to Cart